Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success
Ipsen Is On The Lookout For Pre-Clinical Assets That Are Associated With Biomarkers
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
